4//SEC Filing
DAVIS STEPHEN 4
Accession 0001415889-24-021724
CIK 0001070494other
Filed
Aug 19, 8:00 PM ET
Accepted
Aug 20, 6:40 PM ET
Size
9.3 KB
Accession
0001415889-24-021724
Insider Transaction Report
Form 4
DAVIS STEPHEN
EVP, CFO AND CBO
Transactions
- Award
Common Stock
2024-08-16+17,333→ 173,520 total - Award
Common Stock
2024-08-16+44,782→ 218,302 total - Sale
Common Stock
2024-08-19$15.28/sh−31,747$485,094→ 186,555 total
Footnotes (5)
- [F1]Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target.
- [F2]Includes 956 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024.
- [F3]Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.
- [F4]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.325, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Documents
Issuer
ACADIA PHARMACEUTICALS INC
CIK 0001070494
Entity typeother
Related Parties
1- filerCIK 0001131146
Filing Metadata
- Form type
- 4
- Filed
- Aug 19, 8:00 PM ET
- Accepted
- Aug 20, 6:40 PM ET
- Size
- 9.3 KB